LLY - FDA accepts Lilly and Dicerna's cardiometabolic diseases IND

Dicerna Pharmaceuticals (DRNA) announces that the U.S. FDA has accepted the Investigational New Drug (“IND”) application filed by Eli Lilly (LLY) for LY3819469, which is a potential treatment of cardiometabolic diseases.LY3819469, which is an investigational GalXC RNAi candidate targeting the LPA gene, is the second clinical-stage candidate to emerge from Dicerna’s collaboration with Lilly.The IND milestone triggers a $10M payment to Dicerna and enables Lilly to initiate a Phase 1 clinical trial of the treatment.Under the agreement with Lilly, Dicerna is eligible to receive up to $350M in development and commercialization milestones for each GalXC hepatocyte target and $355M for each non-hepatocyte target, as well as tiered royalties ranging from the mid-single-digits to low double-digits on potential product sales.

For further details see:

FDA accepts Lilly and Dicerna's cardiometabolic diseases IND